Introduction: Gastric infection by “Helicobacter pylori” remains a topical issue due to the evolving scientific data concerning its pathophysiology, the diseases and pathologies concerned, which now extend beyond the gastric or digestive sphere, and the treatment methods faced with the development of antibiotic resistance. Diagnosis of infection involves two inseparable aspects: identification of the bacterium itself and identification of the endoscopic and histological lesions caused by the bacterium. Objective: To evaluate the rate of eradication of Helicobacter pylori infection by bismuth quadruple therapy and concomitant treatment. Patients and methods: This was a prospective, cross-sectional, analytical study of all outpatients in the hepato-gastroenterology department during the study period from 1 January 2022 to 30 November 2023. All patients had undergone oeso-gastroduodenal fibroscopy and the diagnosis was made by histological examination of the gastric biopsy. Results: Our 113 patients comprised 68 men and 46 women. The sex ratio was 1.48 in favour of men. The mean age of our patients was 40.28 years, with extremes of 13 and 80 years. The clinical signs that prompted oeso-gastroduodenal fibroscopy were as follows: epigastralgia (69.91%), dyspepsia (14.16%), vomiting (7.08%), gastro-oesophageal reflux (6.19%) and altered general condition with weight loss (2.65%). The endoscopic lesions were: gastropathy (antral, fundic and diffuse: antro-fundial) (69.02%), bulbar ulcer (6.19%), gastric ulcer (5.31%). Helicobacter pylori infection was associated with chronic gastritis in all our patients; it was mild in 50%, moderate in 41% and severe in 9%. The eradication rate of Helicobacter pylori according to the treatment protocol used was 92.30% for bismuth quadruple therapy and 94.12% for concomitant quadruple therapy. Conclusion: The eradication rate of Helicobacter pylori in our study was 92.30% and 94.12% respectively for bismuth quadritherapy and concomitant therapy. Therapeutic compliance was good in 89.60% for all protocols combined, despite the occurrence of side effects in 36.22% of cases.
References
[1]
Zamani, M., Ebrahimtabar, F., Zamani, V., et al. (2018) Systematic Review with Meta-Analysis: The Worldwide Prevalence of Helicobacter pylori Infection. Alimentary Pharmacology & Therapeutics, 47, 868-876. https://doi.org/10.1111/apt.14561
[2]
Heluwaert, F., Nahon, S., Lesgourges, B., et al. (2016) JFHOD 2018: CO 54-Pylori Hebdo: Results of a Practice Survey on the Management of Helicobacter pylori in 31 ANGH Centres in 2014.
[3]
Heluwaert, F., Tracanelli, L., Abousalihac, et al. (2018) JFHOD 2018: CO 76-Diagnosis and Treatment of Helicobacter pylori Infection at the Geneva Hospital Centre, Contribution of PCR and Culture for Diagnosis.
[4]
Mataly, H.M. (2007) Epidemiology of Helicobacter pylori Infection. Best Practice and Research Clinical Gastroenterology, 21, 205-214.
[5]
Agbor, N.E., Esemu, S.N., et al. (2018) Helicobacter pylori in Patients with Gastritis in West Cameroon: Prevalence and Risk Factors for Infection. BMC Research Notes, 11, Article No. P559. https://doi.org/10.1186/s13104-018-3662-5
[6]
Choi, I., Kim, C.G., Lee, J.Y., et al. (2020) Family History of Gastric Cancer and Helicobacter pylori Treatment. The New England Journal of Medicine, 382, 427-436. https://doi.org/10.1056/NEJMoa1909666
[7]
Fallone, C.A., Chiba, N., Van Zanten, S.V., Fischbach, L., Gisbert, J.P., Hunt, R.H., et al. (2016) The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology, 151, 51-69. https://doi.org/10.1053/j.gastro.2016.04.006
Attia, K.A., N’Dri Yoman, T., Diomandé, M.I., et al. (2001) Clinical and Histological Aspects of Chronic Helicobacter pylori Gastritis in the Ivory Coast: Study of 102 Patients. Bulletin de la Société de Pathologie Exotique, 94, 5-7.
[10]
Itoudi Bignoumba, P.E., Maganga Moussavou, I.F., Ziza, N., et al. (2019) Helicobacter pylori au Centre Hospitalier Universitaire de Libreville: Aspects épidémiologiques et Cliniques à Propos de 728 Patients. Health Sciences and Diseases, 20, 64-68.
[11]
Glupezynski, Y. (1994) Epidemiology of Helicobacter pylori Infection and Diagnostic Methods. Annales Médicales de Nancy et de l’Est, 33, 89-93.
[12]
Hunt, R.H., Xiao, S.D., Megraud, F., et al. (2011) Helicobacter pylori in Developing Countries. World Gastroenterology Organization Global Guideline. Journal of Gastrointestinal and Liver Diseases, 20, 299-304.
[13]
Darre, T., Amégbor, K., Bagny, A., Sewa, E., Tchangai Sakiye, B.E., et al. (2013) Histo-Epidemiological Profile of Chronic Gastritis and Helicobacter pylori Infection: A Propos of 296 Biopsy Cases in Togo. Journal Africain de Chirurgie Digestive, 13, 1426-1430.
[14]
Zhu, X.Y., Du, J., Wu, J., et al. (2017) [Influence of Saccharomyces boulardii Sachets Combined with Bismuth Quadruple Therapy for Initial Helicobacter pylori Eradication]. Chinese Medical Journal, 97, 2353-2356.
[15]
Coulibaly, B. (2012) Epidemiological and Histopathological Aspects of Chronic Atrophic Gastritis in Mali. Mémoire CES, Abidjan.
[16]
Lamarque, D., Burucoa, C., Courillon, M., et al. (2017) Recommendations on the Treatment of Helicobacter pylori Infection in Adults. Hepato-Gastroenterology, 24, 157-170.
[17]
Nyssen, O.P., Perez-Aisa, A., Rodrigo, L., et al. (2020) Bismuth Quadruple Regimen with Tetracycline or Doxycycline versus Three-in-One Single Capsule as Third Line Rescue Therapy for Helicobacter pylori Infection: Spanish Data of the European Helicobacter pylori Registry (Hp-EuReg). Helicobacter, 25, e12722. https://doi.org/10.1111/hel.12722
[18]
De Korwin, J.D., Kalach, N. and Raymond, J. (2014) Helicobacter pylori. EMC Gastroenterology, 93, 1-11.
[19]
Relevance of Care Sheets on the Diagnosis and Treatment of H. pylori Infection in Adults and Report on the Relevance of Procedures and Drug Prescriptions in an Adult Patient Infected with Helicobacter pylori. https://www.has-santé.fr/portail/jcms/c-2774179/fr/
[20]
Li, B.-Z., Threapleton, D.E., Wang, J.Y., Xu, J.-M., et al. (2015) Comparative Effectiveness and Tolerance of Treatments for Helicobacter pylori: Systemic Review and Network Meta-Analysis. BMJ, 351, Article h4052. https://doi.org/10.1136/bmj.h4052
[21]
Lui, K.S., Hung, I.F., Seto, W.K., Hsu, A.S., Lam, F.Y., et al. (2014) Ten Days Sequential versus 10 Days Modified Bismuth Quadruple Therapy as Empirical First-Line and Second-Line Treatment for Helicobacter pylori in Chinese Patients: An Open Label, Randomized, Crossover Trial. Gut, 63, 1410-1415. https://doi.org/10.1136/gutjnl-2013-306120
[22]
Zeriouh, M., Abda, N., Khannoussi, W., et al. (2020) Concurrent Quadruple Therapy, Sequential Treatment or Dual Therapy for the Eradication of Helicobacter pylori? Prospective Randomised Study, Preliminary Results. Société Francaise Hépato-Gastroentérologie, 21, 23-27.
[23]
Bouchabou, B., Hamzouil, L., Medhiuob, M., et al. (2020) Treatment of Helicobacter pylori Infection: Concomitant versus Sequential Quadritherapy. A Prospective Single-Centre Tunisian Study. Journées Francophones d’Hépato-Gastroentérologie et d’Oncologie Digestive 2020, Paris, 26-29 March 2020, 152.
[24]
Lecomte, T., Godart, B. and Rahmi, G. (2017) Recommandations: Cancers superficiels du tube digestif. Prise en charge endoscopique des cancers superficiels de l’estomac. Acta Endoscopica, 47, 180-186. https://doi.org/10.1007/s10190-017-0599-9
[25]
Pimentel-Nunes, P., Libanio, D., Marcos Pinto, R., et al. (2019) Management of Epithelial Precancerous Conditions and Lesions in the Stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) Guideline Update 2019. Endoscopy, 51, 365-388. https://doi.org/10.1055/a-0859-1883
